What is the optimal regimen for vitamin D?

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study

1998 • 2,334 citations

The spectrum of bone disease in end-stage renal failure—An evolving disorder

1993 • 737 citations

Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.

1984 • 689 citations

Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D.

1995 • 407 citations

19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.

1998 • 340 citations

Aluminum localization in bone from hemodialyzed patients: Relationship to matrix mineralization

1981 • 271 citations

Action of 1,25-Dihydroxycholecalciferol, a Potent, Kidney-Produced Metabolite of Vitamin D₃, in Uremic Man

1972 • 260 citations

Hyperphosphatemia: Its Consequences and Treatment in Patients With Chronic Renal Disease

1992 • 242 citations

The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.

1989 • 237 citations

The hyperparathyroidism of chronic renal failure: A disorder of growth

1997 • 211 citations

A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia

1995 • 201 citations

Pathogenesis of Secondary Hyperparathyroidism

1994 • 147 citations

Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure

1996 • 144 citations

Effective suppression of parathyroid hormone by 1α-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism

1997 • 137 citations

A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content

1997 • 136 citations

Disappearance of Aluminic Bone Disease in a Long Term Asymptomatic Dialysis Population Restricting Al(OH)<sub>3</sub> Intake: Emergence of an Idiopathic Adynamic Bone Disease Not Related to Aluminum

1989 • 105 citations

Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man.

1976 • 93 citations

1-ALPHA-HYDROXYCHOLECALCIFEROL AS A SUBSTITUTE FOR THE KIDNEY HORMONE 1,25-DIHYDROXYCHOLECALCIFEROL IN CHRONIC RENAL FAILURE

1973 • 93 citations

Parathyroid hormone metabolism and its potential as a uremic toxin

1980 • 78 citations

Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism.

1993 • 75 citations

Pulse Oral Calcitriol for the Treatment of Hyperparathyroidism in Patients on Continuous Ambulatory Peritoneal Dialysis: Preliminary Observations

1992 • 73 citations

Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study

1996 • 66 citations

Vitamin D analogues

1998 • 62 citations

Suppressive Effect of 1,25-Dihydroxyvitamin D₃on Circulating Parathyroid Hormone in Acute Renal Failure

1981 • 45 citations

‘Pulse’ oral calcitriol in uraemic patients: rapid modification of parathyroid response to calcium

1992 • 32 citations

Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial

1998 • 31 citations

Metabolism of 1 alpha-hydroxyvitamin D2 to activated dihydroxyvitamin D 2 metabolites decreases endogenous 1 alpha, 25-dihydroxyvitamin D 3 in rats and monkeys.

1995 • 30 citations

Long-Term Suppression of Secondary Hyperparathyroidism by Intravenous 1α-Hydroxy vitamin D<sub>3</sub> in Patients on Chronic Hemodialysis

1992 • 16 citations

Calcitriol in the Management of Renal Osteodystrophy

1996 • 14 citations

Parathyroid pathophysiology in uraemia

1996 • 7 citations